Climbing as an Add-On Treatment Option for Patients with Severe Anxiety Disorders and PTSD: Feasibility Analysis and First Results of a Randomized Controlled Longitudinal Clinical Pilot Trial

被引:5
|
作者
Bichler, Carina S. [1 ]
Niedermeier, Martin [1 ]
Huefner, Katharina [2 ]
Galffy, Matyas [2 ]
Gostner, Johanna M. [3 ]
Nelles, Philipp [2 ]
Schoettl, Stefanie E. [1 ]
Sperner-Unterweger, Barbara [2 ]
Kopp, Martin [1 ]
机构
[1] Univ Innsbruck, Dept Sport Sci, Fuerstenweg 185, A-6020 Innsbruck, Austria
[2] Innsbruck Med Univ, Univ Hosp Psychiat 2, Dept Psychiat Psychotherapy Psychosomat & Med Psy, Anichstr 35, A-6020 Innsbruck, Austria
[3] Med Univ Innsbruck, Inst Med Biochem, Bioctr, Innrain 80-82, A-6020 Innsbruck, Austria
关键词
anxiety disorder; post-traumatic stress disorder; exercise; physical activity; climbing therapy; biomarker; QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; PHYSICAL-ACTIVITY; SERUM TRYPTOPHAN; NORDIC WALKING; EXERCISE; PEOPLE; HEALTH; METAANALYSIS;
D O I
10.3390/ijerph191811622
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Background: Exercise has considerable effects on physical and psychological health. Anxiolytic effects of climbing exercise have been found in people suffering from depression. However, there are no studies on patients with severe anxiety disorders or post-traumatic stress disorder (PTSD) practicing climbing as add-on treatment. Additionally, many studies on physical therapy fail to use adequate active control groups. Therefore, this study aimed to investigate the feasibility of a four-week climbing exercise program for patients with anxiety disorders or PTSD in comparison to a standard exercise treatment and a social control group. Methods: Outpatients diagnosed with anxiety disorders or PTSD (F 40, F 41, F 43.1 according to ICD-10) were randomly assigned to (a) climbing exercise (n = 27), (b) Nordic walking exercise (n = 23), or (c) control condition (n = 23) providing the same amount of social contact for eight sessions of 90 minutes each. Psychological parameters (symptom severity, worry symptoms, self-efficacy, quality of life) and biological parameters were assessed at the beginning and at the end of the four-week program. Additionally, follow-up assessments were conducted three and six months after the program ended. Results: Sixty outpatients (75% female) aged 18-65 years with a longstanding history of a mental disorder (>10 years) and classified as treatment-resistant (95%) and with averaging 3.8 psychiatric comorbidities completed the pilot trial. After participation, symptoms of anxiety disorders were significantly reduced (p = 0.003), and health-related characteristics significantly improved (depression symptoms: p < 0.001, worry symptoms: p < 0.001, self-efficacy: p < 0.001, quality of life-physical health: p = 0.002, quality of life-psychological health: p = 0.006) in all groups. The feasibility of conducting climbing exercises for the patient groups could be demonstrated, and a general acceptance in the groups was recorded. No significant time-by-group interactions were found. At the completion of the program, psychological parameters improved, while biological parameters remained the same in all three groups. Conclusions: Participation in the climbing group as well as in Nordic walking and social contact groups demonstrated beneficial results in patients with anxiety disorders and PTSD with severe mental burden. Nevertheless, climbing did not show any additional clinically relevant benefits compared to Nordic walking or social contact. Studies with larger sample sizes and qualitative insights are needed to further evaluate the possible benefits of climbing in this population.
引用
收藏
页数:18
相关论文
共 49 条
  • [31] Effectiveness of a self-management training for patients with chronic and treatment resistant anxiety or depressive disorders on quality of life, symptoms, and empowerment: results of a randomized controlled trial
    Zoun, Maringa H. H.
    Koekkoek, Bauke
    Sinnema, Henny
    van der Feltz-Cornelis, Christina M.
    van Balkom, Anton J. L. M.
    Schene, Aart H.
    Smit, Filip
    Spijker, Jan
    BMC PSYCHIATRY, 2019, 19 (1)
  • [32] Enhancing chronic migraine preventive therapy: low-level 810 nm laser acupuncture as an add-on treatment for patients with unsatisfactory pharmacological effect, a pilot single-blind randomized controlled trial
    Wu, Huan-Yun
    Wang, Chi-Sheng
    Liu, Yuan-Chen
    Chung, Ching-Chun
    Chen, Wan-Ling
    Tsai, Chia-, I
    Hsu, Chiann-Yi
    Chou, Chi-Hsiang
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2024, 24 (01)
  • [33] RETRACTED: The randomized clinical trial results of the anxiety treatment in patients with somatoform dysfunction and neurotic disorders (Retracted article. See vol. 12, 2022)
    Parfenov, Vladimir Anatolevich
    Kamchatnov, Pavel Rudolfovich
    Khasanova, Dina Rustemovna
    Bogdanov, Enver Ibragimovich
    Lokshtanova, Tatiana Markovna
    Amelin, Aleksandr Vitalevich
    Maslova, Natalya Nikolaevna
    Pizova, Nataliia Vyacheslavovna
    Belskaya, Galina Nikolaevna
    Barantsevich, Evgeny Robertovich
    Duchshanova, Gulsum Abdurahmanovna
    Kamenova, Saltanat Ualihanovna
    Kolokolov, Oleg Vladimirovich
    Glazunov, Alexey Borisovich
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [34] EVENAMIDE AS ADD-ON TREATMENT FOR PATIENTS WITH CHRONIC SCHIZOPHRENIA NOT RESPONDING ADEQUATELY TO THEIR CURRENT ANTIPSYCHOTIC MEDICATION: RESULTS OF A POTENTIALLY PIVOTAL, PHASE II/III, INTERNATIONAL, RANDOMIZED, DOUBLE BLIND, PLACEBO- CONTROLLED TRIAL
    Anand, Ravi
    Turolla, Alessio
    Chinellato, Giovanni
    Giuliani, Rodolfo
    Hartman, Richard
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2025, 28 : i350 - i351
  • [35] EVENAMIDE AS ADD-ON TREATMENT FOR TREATMENT-RESISTANT SCHIZOPHRENIA (TRS) PATIENTS NOT BENEFITING FROM ANTIPSYCHOTICS: DESIGN OF A PHASE 3, POTENTIALLY PIVOTAL, INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL
    Anand, Ravi
    Turolla, Alessio
    Chinellato, Giovanni
    Giuliani, Rodolfo
    Hartman, Richard
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2025, 28 : i353 - i354
  • [36] A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial
    Lombardo, Flavia L.
    Alegiani, Stefania Spila
    Mayer, Flavia
    Cipriani, Marta
    Lo Giudice, Maria
    Ludolph, Albert Christian
    McDermott, Christopher J.
    Corcia, Philippe
    Van Damme, Philip
    van den Berg, Leonard H.
    Hardiman, Orla
    Nicolini, Gabriele
    Vanacore, Nicola
    Dickie, Brian
    Albanese, Alberto
    Puopolo, Maria
    TRIALS, 2023, 24 (01)
  • [37] A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial
    Flavia L. Lombardo
    Stefania Spila Alegiani
    Flavia Mayer
    Marta Cipriani
    Maria Lo Giudice
    Albert Christian Ludolph
    Christopher J. McDermott
    Philippe Corcia
    Philip Van Damme
    Leonard H. Van den Berg
    Orla Hardiman
    Gabriele Nicolini
    Nicola Vanacore
    Brian Dickie
    Alberto Albanese
    Maria Puopolo
    Trials, 24
  • [38] Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial
    Tsianakas, A.
    Luger, T. A.
    Radin, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) : 406 - 414
  • [39] Randomized Controlled Trial of Switching to Tenofovir Disoproxil Fumarate Monotherapy in Lamivudine-Resistant Chronic Hepatitis B Patients with Undetectable HBV Viral Load under Lamivudine/-Adefovir Add-on Therapy: The First Interim Analysis
    Huang, Yi-Hsiang
    Su, Chien-Wei
    Wang, Yuan-Jen
    Huang, Yi-Shin
    Lee, Kuei-Chuan
    Hou, Ming-Chih
    Lin, Han-Chieh
    HEPATOLOGY, 2014, 60 : 1108A - 1109A
  • [40] Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial (Sep, 10.1007/s00213-022-06225-2, 2022)
    Mishra, Archana
    Reeta, K. H.
    Sarangi, Sudhir Chandra
    Maiti, Rituparna
    Sood, Mamta
    PSYCHOPHARMACOLOGY, 2022, 239 (11) : 3537 - 3537